by DealForma Analysts | Jun 10, 2022 | Deal of the Month
Deal of the Month May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation May 2022 Top Biopharma Deal Upfront Dragonfly Therapeutics development and commercialization deal with Gilead Sciences for solid...
by DealForma Analysts | May 10, 2022 | Deal of the Month
Deal of the Month April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment April 2022 Top Biopharma Deal Upfront Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors Announced: April...
by DealForma Analysts | Apr 28, 2022 | Deal of the Month
Deal of the Month March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation March 2022 Top Biopharma Deal Upfront IGM development and commercialization deal with Sanofi for cancer, immunology, and...
by DealForma Analysts | Mar 10, 2022 | Deal of the Month
Deal of the Month February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment February 2022 Top Biopharma Deal Upfront Heidelberg development and commercialization deal with Huadong for HDP-101, HDP-103, and options for two more...
by DealForma Analysts | Feb 10, 2022 | Deal of the Month
Deal of the Month January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases January 2022 Top Biopharma Deal Upfront Beam research partnership with Pfizer with a license option for up to three therapies for rare...
by DealForma Analysts | Jan 10, 2022 | Deal of the Month
Deal of the Month December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments December 2021 Top Biopharma Deal Upfront Foghorn partnership with Loxo (Eli Lilly) for selective BRM oncology therapies Announced: December...
by DealForma Analysts | Dec 8, 2021 | Deal of the Month
Deal of the Month November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline November 2021 Top Biopharma Deal Upfront Owkin discovery and development deal with Sanofi for...
by DealForma Analysts | Nov 5, 2021 | Deal of the Month
Deal of the Month October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies Top Biopharma Partnership by Upfront Cash and Equity October 2021 Xencor development and commercialization deal with Janssen for plamotamab and XmAb...
by DealForma Analysts | Oct 7, 2021 | Deal of the Month
Deal of the Month September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy Top Biopharma Partnership by Upfront Cash and Equity September 2021 REGENXBIO development and commercialization deal with AbbVie for RGX-314...
by DealForma Analysts | Sep 8, 2021 | Deal of the Month
Deal of the Month August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors Top Biopharma Partnership by Upfront Cash and Equity August 2021 RemeGen development and commercialization deal with Seagen for disitamab...
